Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients
- Taylor, Emma
- Jones, Mark
- Hourigan, Matthew J.
- Johnson, David W.
- Gill, Devinder S.
- Isbel, Nicole
- Hawley, Carmel M.
- Marlton, Paula
- Gandhi, Maher K.
- Campbell, Scott B.
- Mollee, Peter
Publication date
October 2015
DOI Publisher
Oxford University Press (OUP) ISSN
0931-0509 Citation count (estimate)
2Abstract
Background. The optimal reduction of immunosuppressive therapy (IST) in renal transplant patients with post-transplant lymphoproliferative disorders (PTLDs) is uncertain. As chemotherapy is immunosuppressive, IST may be stopped during this time without compromising graft function. Subsequent long-term reduction of IST reduces relapse risk, but may increase risk of graft rejection
Add to ORKG